Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Bank Julius Baer & Co. Ltd Zurich

Bank Julius Baer & Co. Ltd Zurich trimmed its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 1.2% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 22,500 shares of the medical equipment provider’s stock after selling 277 shares during the period. Bank Julius Baer & Co. Ltd Zurich’s holdings in Hologic were worth $1,608,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. McGlone Suttner Wealth Management Inc. acquired a new stake in shares of Hologic during the 4th quarter worth $27,000. Venturi Wealth Management LLC acquired a new stake in shares of Hologic during the 3rd quarter worth $29,000. NBC Securities Inc. acquired a new stake in shares of Hologic during the 3rd quarter worth $33,000. Deseret Mutual Benefit Administrators increased its holdings in shares of Hologic by 42.2% during the 3rd quarter. Deseret Mutual Benefit Administrators now owns 522 shares of the medical equipment provider’s stock worth $36,000 after buying an additional 155 shares during the last quarter. Finally, Massmutual Trust Co. FSB ADV boosted its position in Hologic by 69.4% during the 4th quarter. Massmutual Trust Co. FSB ADV now owns 554 shares of the medical equipment provider’s stock worth $40,000 after purchasing an additional 227 shares during the period. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Hologic

In other news, CFO Karleen Marie Oberton sold 14,940 shares of the stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $75.00, for a total transaction of $1,120,500.00. Following the transaction, the chief financial officer now owns 103,916 shares of the company’s stock, valued at $7,793,700. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, Director Charles J. Dockendorff sold 1,465 shares of the stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $76.21, for a total transaction of $111,647.65. Following the transaction, the director now owns 1,572 shares of the company’s stock, valued at $119,802.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Karleen Marie Oberton sold 14,940 shares of the stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $75.00, for a total transaction of $1,120,500.00. Following the sale, the chief financial officer now owns 103,916 shares in the company, valued at approximately $7,793,700. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 32,846 shares of company stock valued at $2,473,443. Insiders own 1.75% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on HOLX shares. Evercore ISI upped their price target on shares of Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a research report on Thursday, April 4th. Citigroup raised shares of Hologic from a “neutral” rating to a “buy” rating and upped their price target for the stock from $80.00 to $95.00 in a research report on Wednesday, April 3rd. William Blair reaffirmed an “outperform” rating on shares of Hologic in a research report on Friday, February 2nd. UBS Group upped their price target on shares of Hologic from $78.00 to $79.00 and gave the stock a “neutral” rating in a research report on Friday, February 2nd. Finally, StockNews.com cut shares of Hologic from a “buy” rating to a “hold” rating in a research report on Friday, March 8th. Six analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $87.00.

Hologic Stock Performance

NASDAQ:HOLX opened at $75.98 on Friday. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.89 and a quick ratio of 3.18. The firm has a 50-day moving average of $76.03 and a two-hundred day moving average of $72.78. The stock has a market cap of $17.83 billion, a P/E ratio of 36.01, a PEG ratio of 2.56 and a beta of 1.00. Hologic, Inc. has a 1-year low of $64.02 and a 1-year high of $87.88.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.95 by $0.03. The company had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $989.32 million. Hologic had a net margin of 12.98% and a return on equity of 18.91%. The firm’s revenue for the quarter was down 5.7% on a year-over-year basis. During the same period in the prior year, the company posted $1.07 EPS. On average, research analysts expect that Hologic, Inc. will post 4.01 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.